Tracking Response to Antidepressants in Advance of Investigational Trials

Description

TRAIT is an open-label observational study to evaluate treatment response to selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs) among individuals meeting criteria for Major Depressive Disorder (MDD) and seeking enrollment in investigational trials.

Conditions

Major Depressive Disorder

Talk to us

Study Overview

On this page

Study Details

Study overview

TRAIT is an open-label observational study to evaluate treatment response to selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs) among individuals meeting criteria for Major Depressive Disorder (MDD) and seeking enrollment in investigational trials.

Tracking Response to Antidepressants in Advance of Investigational Trials

Tracking Response to Antidepressants in Advance of Investigational Trials

Condition
Major Depressive Disorder
Intervention / Treatment

-

Contacts and Locations

Watertown

Adams Clinical, Watertown, Massachusetts, United States, 02472

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participant has signed an ICF prior to any study-specific procedures being performed.
  • * Participant is male or female of age ≥ 18 years old.
  • * Participant has a diagnosis of MDD as confirmed by the MINI semi-structured diagnostic interview and ≥ 14 HAM-D total score.
  • * Participant is in good physical health and, in the opinion of the investigator, is a suitable candidate for treatment with an ADT.
  • * Participant is pregnant, breast-feeding, or planning to become pregnant.
  • * A history or presence of a clinically significant hepatic, renal, gastrointestinal, cardiovascular, endocrine, respiratory, immunologic, hematologic, dermatologic, or neurologic abnormality, which in the opinion of the investigator may impact participant safety or study results.
  • * Participant has a history of any psychiatric condition other than MDD, which in the opinion of the investigator is primary, or any other psychiatric or neurologic disorder or symptom that could pose undue risk to the participant or compromise the study.
  • * Any participant who represents an acute suicidal risk in the opinion of the investigator.
  • * Moderate or severe substance use disorder within 90 days prior to screen, according to DSM-5 criteria that in the opinion of the investigator could pose undue risk to the participant, or compromise the study.
  • * Any condition that, in the opinion of the investigator, makes the participant unsuitable for the study.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Adams Clinical,

Stephanie Ellickson, PhD, PRINCIPAL_INVESTIGATOR, Adams Clinical

Study Record Dates

2023-12-31